MX2022003930A - Conjugados de péptido de camptotecina. - Google Patents
Conjugados de péptido de camptotecina.Info
- Publication number
- MX2022003930A MX2022003930A MX2022003930A MX2022003930A MX2022003930A MX 2022003930 A MX2022003930 A MX 2022003930A MX 2022003930 A MX2022003930 A MX 2022003930A MX 2022003930 A MX2022003930 A MX 2022003930A MX 2022003930 A MX2022003930 A MX 2022003930A
- Authority
- MX
- Mexico
- Prior art keywords
- camptothecin
- peptide conjugates
- camptothecin peptide
- conjugates
- compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962911060P | 2019-10-04 | 2019-10-04 | |
| PCT/US2020/054137 WO2021067861A1 (en) | 2019-10-04 | 2020-10-02 | Camptothecin peptide conjugates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022003930A true MX2022003930A (es) | 2022-07-04 |
Family
ID=73013821
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022003930A MX2022003930A (es) | 2019-10-04 | 2020-10-02 | Conjugados de péptido de camptotecina. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240277860A1 (https=) |
| EP (1) | EP4037717A1 (https=) |
| JP (1) | JP2022550851A (https=) |
| KR (1) | KR20220079606A (https=) |
| CN (1) | CN114929284A (https=) |
| AU (1) | AU2020356955A1 (https=) |
| CA (1) | CA3152316A1 (https=) |
| IL (1) | IL291686A (https=) |
| MX (1) | MX2022003930A (https=) |
| WO (1) | WO2021067861A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020020466A2 (pt) * | 2018-04-06 | 2021-01-12 | Seattle Genetics, Inc. | Conjugados de peptídeo de camptotecina |
| TWI851577B (zh) | 2018-06-07 | 2024-08-11 | 美商思進公司 | 喜樹鹼結合物 |
| CA3183602A1 (en) * | 2020-05-13 | 2021-11-18 | Seagen Inc. | Methods of treating cancer using a combination of anti-cd30 antibody-drug conjugates |
| CA3213625A1 (en) * | 2021-03-18 | 2022-09-22 | Seagen Inc. | Selective drug release from internalized conjugates of biologically active compounds |
| BR112023018676A2 (pt) | 2021-03-18 | 2023-10-10 | Seagen Inc | Conjugado anticorpo-fármaco, composição farmacêutica, métodos de tratamento de uma doença ou condição e de um câncer, e, composição de conjugado ligante-fármaco |
| WO2023178289A2 (en) * | 2022-03-17 | 2023-09-21 | Seagen Inc. | Camptothecin conjugates |
| EP4523704A1 (en) * | 2022-05-12 | 2025-03-19 | Hainan Simcere Zaiming Pharmaceutical Co., Ltd. | Camptothecin derivative and ligand-drug conjugate |
| IL317271A (en) * | 2022-05-30 | 2025-01-01 | Medilink Therapeutics Suzhou Co Ltd | Preparation method for Drug Linker Conjugate and between them |
| WO2024020734A1 (en) * | 2022-07-25 | 2024-02-01 | Immunogen, Inc. | Novel processes for preparing camptothecin derivatives |
| JP2025529237A (ja) * | 2022-08-30 | 2025-09-04 | ピノットバイオ インコーポレイテッド | カンプトセシン系薬物が抗原結合親和性の低い抗体にリンカーを介して連結された抗体薬物複合体 |
| KR20240035370A (ko) * | 2022-09-08 | 2024-03-15 | 주식회사 피노바이오 | 신규 캄토테신 유도체 및 이를 포함하는 운반체-약물 접합체 |
| WO2024078449A1 (en) | 2022-10-09 | 2024-04-18 | LaNova Medicines Limited | Compounds, compositions and methods |
| WO2024114318A1 (zh) * | 2022-11-29 | 2024-06-06 | 四川科伦博泰生物医药股份有限公司 | 药物连接子化合物及其制备方法和用途 |
| WO2024129756A1 (en) | 2022-12-13 | 2024-06-20 | Seagen Inc. | Site-specific engineered cysteine antibody drug conjugates |
| WO2024230301A1 (zh) * | 2023-05-09 | 2024-11-14 | 诺灵生物医药科技(北京)有限公司 | 一种抗体偶联药物及其用途 |
| WO2024230678A1 (zh) * | 2023-05-11 | 2024-11-14 | 映恩生物科技(上海)有限公司 | 喜树碱类化合物及其偶联物、其制备方法和用途 |
| WO2025149947A1 (en) | 2024-01-12 | 2025-07-17 | Seagen Inc. | Antibody-drug conjugates |
| WO2025196639A1 (en) | 2024-03-21 | 2025-09-25 | Seagen Inc. | Cd25 antibodies, antibody-drug conjugates, and uses thereof |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2036891B (en) | 1978-12-05 | 1983-05-05 | Windsor Smith C | Change speed gear |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| DE3689123T2 (de) | 1985-11-01 | 1994-03-03 | Xoma Corp | Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung. |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| WO1990006952A1 (fr) | 1988-12-22 | 1990-06-28 | Kirin-Amgen, Inc. | Facteur de stimulation de colonies de granulocytes modifies chimiquement |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5166322A (en) | 1989-04-21 | 1992-11-24 | Genetics Institute | Cysteine added variants of interleukin-3 and chemical modifications thereof |
| US5342947A (en) * | 1992-10-09 | 1994-08-30 | Glaxo Inc. | Preparation of water soluble camptothecin derivatives |
| JP2763020B2 (ja) | 1995-04-27 | 1998-06-11 | 日本電気株式会社 | 半導体パッケージ及び半導体装置 |
| US5672662A (en) | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
| JP4046354B2 (ja) | 1996-03-18 | 2008-02-13 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 増大した半減期を有する免疫グロブリン様ドメイン |
| EP0964702B1 (en) | 1996-08-02 | 2006-10-04 | Ortho-McNeil Pharmaceutical, Inc. | Polypeptides having a single covalently bound n-terminal water-soluble polymer |
| US6629995B1 (en) * | 2000-03-31 | 2003-10-07 | Super Gen, Inc. | Camptothecin conjugates |
| US6825206B1 (en) * | 2000-11-16 | 2004-11-30 | Research Triangle Institute | Camptothecin compounds with a thioether group |
| US7090843B1 (en) | 2000-11-28 | 2006-08-15 | Seattle Genetics, Inc. | Recombinant anti-CD30 antibodies and uses thereof |
| JP5122441B2 (ja) | 2005-04-19 | 2013-01-16 | シアトル ジェネティックス， インコーポレイテッド | ヒト化抗ｃｄ７０結合剤およびその使用 |
| WO2007005644A2 (en) | 2005-07-01 | 2007-01-11 | Concert Pharmaceuticals Inc. | Novel aryloxypropanamines |
| WO2007005643A2 (en) | 2005-07-01 | 2007-01-11 | Concert Pharmaceuticals Inc. | Novel aryloxyphenylpropanamines |
| KR101380190B1 (ko) | 2005-07-29 | 2014-04-11 | 콘서트 파마슈티컬즈, 인크. | 벤조 〔ｄ〕〔１,３〕―디옥솔 유도체 |
| AU2006275702A1 (en) | 2005-07-29 | 2007-02-08 | Concert Pharmaceuticals Inc. | Novel pharmaceutical compounds |
| EA020696B1 (ru) * | 2007-10-12 | 2015-01-30 | Сиэтл Дженетикс, Инк. | Способ лечения лимфомы ходжкина с использованием комбинации гемцитабина и конъюгата антитела против cd30 с ауристатином |
| EP2589609A1 (en) * | 2011-11-03 | 2013-05-08 | Pierre Fabre Medicament | Antigen binding protein and its use as addressing product for the treatment of cancer |
| WO2013173337A2 (en) | 2012-05-15 | 2013-11-21 | Seattle Genetics, Inc. | Self-stabilizing linker conjugates |
| US20160106861A1 (en) * | 2013-04-26 | 2016-04-21 | Spirogen Sarl | Axl antibody-drug conjugate and its use for the treatment of cancer |
| NZ758049A (en) | 2013-10-15 | 2024-03-22 | Seagen Inc | Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics |
| KR102442906B1 (ko) * | 2013-12-19 | 2022-09-14 | 씨젠 인크. | 표적화된-약물 컨쥬게이트와 함께 사용되는 메틸렌 카바메이트 링커 |
| DK3270965T3 (da) | 2015-03-18 | 2020-06-08 | Seattle Genetics Inc | Cd48-antistoffer og konjugater deraf |
| SG10202005460RA (en) | 2015-06-30 | 2020-07-29 | Seattle Genetics Inc | Anti-ntb-a antibodies and related compositions and methods |
| JP2021095424A (ja) * | 2018-03-28 | 2021-06-24 | 持田製薬株式会社 | 抗癌剤結合アルギン酸誘導体 |
| BR112020020466A2 (pt) * | 2018-04-06 | 2021-01-12 | Seattle Genetics, Inc. | Conjugados de peptídeo de camptotecina |
| TWI851577B (zh) * | 2018-06-07 | 2024-08-11 | 美商思進公司 | 喜樹鹼結合物 |
| CN109675050A (zh) * | 2018-12-27 | 2019-04-26 | 浙江工业大学 | 以喜树碱为母核的类似物与非甾体抗炎药物的偶联物及其制备与应用 |
-
2020
- 2020-10-02 CN CN202080080665.1A patent/CN114929284A/zh active Pending
- 2020-10-02 KR KR1020227015051A patent/KR20220079606A/ko active Pending
- 2020-10-02 WO PCT/US2020/054137 patent/WO2021067861A1/en not_active Ceased
- 2020-10-02 AU AU2020356955A patent/AU2020356955A1/en not_active Abandoned
- 2020-10-02 EP EP20796991.6A patent/EP4037717A1/en not_active Withdrawn
- 2020-10-02 CA CA3152316A patent/CA3152316A1/en active Pending
- 2020-10-02 MX MX2022003930A patent/MX2022003930A/es unknown
- 2020-10-02 US US17/766,208 patent/US20240277860A1/en active Pending
- 2020-10-02 JP JP2022520442A patent/JP2022550851A/ja active Pending
-
2022
- 2022-03-24 IL IL291686A patent/IL291686A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3152316A1 (en) | 2021-04-08 |
| AU2020356955A1 (en) | 2022-04-14 |
| IL291686A (en) | 2022-05-01 |
| JP2022550851A (ja) | 2022-12-05 |
| KR20220079606A (ko) | 2022-06-13 |
| EP4037717A1 (en) | 2022-08-10 |
| WO2021067861A1 (en) | 2021-04-08 |
| US20240277860A1 (en) | 2024-08-22 |
| CN114929284A (zh) | 2022-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022003930A (es) | Conjugados de péptido de camptotecina. | |
| MX2020010458A (es) | Conjugados de camptotecina-peptido. | |
| MX2024008677A (es) | Conjugados de camptotecina. | |
| MX2020012797A (es) | Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso. | |
| CY1125977T1 (el) | Ενωσεiς που αλληλεπιδρουν με τη γλυκανη και μεθοδοι χρησης | |
| CL2024002093A1 (es) | Anticuerpos anti-cd73. | |
| CO2020013252A2 (es) | Dosificación subcutánea de anticuerpos anti-cd38 | |
| AU2018236742B2 (en) | Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same | |
| PH12021553000A1 (en) | Multispecific proteins | |
| EA039072B9 (ru) | Производные майтанзиноида, их конъюгаты и способы применения | |
| PH12017500022A1 (en) | Carrier-antibody compositions and methods of making and using the same | |
| WO2017031458A3 (en) | Anti-dll3 antibody drug conjugates and methods of use | |
| ZA202103867B (en) | Tubulysins and protein-tubulysin conjugates | |
| PH12022550646A1 (en) | Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use | |
| BR112018010279A2 (pt) | novos anticorpos anti-emr2 e métodos de uso | |
| WO2018134681A8 (en) | Anti-tgf-beta antibodies and their use | |
| PH12020551968A1 (en) | Anti-sez6 antibody drug conjugates and methods of use | |
| MX2020011027A (es) | Constructos de anticuerpos biespecíficos trivalentes. | |
| PH12022550318A1 (en) | Treatment of cancers with antibody drug conjugates (adc) that bind to 191p4d12 proteins | |
| WO2020036646A3 (en) | Cancer neoantigens and their utilities in cancer vaccines and tcr-based cancer immunotherapy | |
| MX2018010491A (es) | Proceso para la preparacion de un conjugado anticuerpo-rifamicina. | |
| MX2022015966A (es) | Anticuerpos y metodos para tratar enfermedades asociadas a claudina. | |
| BR112018012884A2 (pt) | novos anticorpos anti-mmp16 e métodos de uso | |
| BR112018012883A2 (pt) | novos anticorpos anti-upk1b e métodos de uso | |
| EP4295903A3 (en) | Compositions and methods for treating farber disease |